Shares of Tyra Biosciences, Inc. (TYRA) are soaring 5.27% in Thursday's trading session following the announcement that the company has dosed the first child in its Phase 2 clinical study for dabogratinib, a potential treatment for pediatric achondroplasia. This significant milestone has sparked investor interest in the clinical-stage biotechnology company.

The Phase 2 study, known as BEACH301, aims to evaluate the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism. Dabogratinib, developed using Tyra's SNÅP platform, is a once-daily oral FGFR3-selective inhibitor. Notably, it is currently the only oral FGFR3-selective inhibitor in clinical development for achondroplasia, potentially positioning Tyra Biosciences at the forefront of treatment options for this condition.

This development marks a crucial step forward in Tyra Biosciences' efforts to address unmet medical needs in skeletal dysplasia. While the initial results from the safety sentinel cohort are not expected until the second half of 2026, the commencement of the trial itself is seen as a positive indicator of the company's progress. Investors appear optimistic about the potential of dabogratinib and its impact on Tyra Biosciences' future prospects, as reflected in today's stock price surge.